America's 10 Highest-Paid CEOs of 2011 (and How They Earned It)
What Happened When Alex Kenjeev Paid His Student Loan in Cash
Celgene (CELG - option chain) shares are rising today after a late-stage study of its blood cancer drug Revlimid was found to be so effective that the study was stopped early. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on CELG.CELG opened this morning at $54.36. So far today the stock has hit a low of $54.02 and a high of $56.16. As of 12:15, CELG is trading at $55.81 up @5.19 (10.3%). The chart for CELG looks bullish and S&P gives CELG a positive 5 STARS (out of 5) strong buy ranking.
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
